V503-010-0007: A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Preadolescents and Adolescents (9 to 14 yea

Project: Other project

StatusFinished
Effective start/end date2/7/142/6/19

Funding

  • Merck Sharp & Dohme Corporation: $134,775.20